A report released today by Zacks Investment Research about Ardelyx Inc (NASDAQ:ARDX) ups the target price to $17.00
- Updated: October 11, 2016
Indicating a possible upside of 0.14%, Zacks Investment Research bumped up the target of Ardelyx Inc (NASDAQ:ARDX) to $17.00
Previously on Thursday March 31, 2016, Ladenburg Thalmann reported about Ardelyx Inc (NASDAQ:ARDX) raised the target price from $0.00 to $21.00. At the time, this indicated a possible upside of 1.79%.
Yesterday Ardelyx Inc (NASDAQ:ARDX) traded 1.08% higher at $14.91. The company’s 50-day moving average is $11.53 and its 200-day moving average is $9.46. The last stock close price is up 57.68% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 397,444 shares of the stock were exchanged, up from an average trading volume of 177,763
See Chart Below
Ardelyx Inc has a 52 week low of $6.36 and a 52 week high of $20.98 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $19.50 with 4 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Ardelyx Inc (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.